Jazz Pharmaceuticals (JAZZ) Interest & Investment Income (2016 - 2025)
Jazz Pharmaceuticals (JAZZ) has 16 years of Interest & Investment Income data on record, last reported at -$45.4 million in Q4 2025.
- For Q4 2025, Interest & Investment Income rose 11.41% year-over-year to -$45.4 million; the TTM value through Dec 2025 reached -$203.9 million, up 14.35%, while the annual FY2025 figure was -$195.1 million, 18.08% up from the prior year.
- Interest & Investment Income reached -$45.4 million in Q4 2025 per JAZZ's latest filing, up from -$48.6 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at -$27.4 million in Q1 2021 and bottomed at -$93.4 million in Q3 2021.
- Average Interest & Investment Income over 5 years is -$66.0 million, with a median of -$69.9 million recorded in 2021.
- Peak YoY movement for Interest & Investment Income: plummeted 240.43% in 2021, then increased 27.11% in 2024.
- A 5-year view of Interest & Investment Income shows it stood at -$88.6 million in 2021, then rose by 16.34% to -$74.1 million in 2022, then increased by 5.13% to -$70.3 million in 2023, then rose by 27.11% to -$51.3 million in 2024, then grew by 11.41% to -$45.4 million in 2025.
- Per Business Quant database, its latest 3 readings for Interest & Investment Income were -$45.4 million in Q4 2025, -$48.6 million in Q3 2025, and -$51.3 million in Q4 2024.